Qiming Venture Partners’ Post

📄 New in Cytotherapy: ‘Accelerating The Development of Genetically Engineered Cellular Therapies: A Framework for Extrapolating Data Across Related Products’ by Mark Stewart, Jeff Allen et al. Advancements in cellular therapy, particularly CAR-T cell treatments, have revolutionized oncology by demonstrating significant clinical benefits, prompting the need for expedited development strategies. A risk-based approach to data extrapolation across genetically engineered cellular therapies offers promise beyond CAR-T cells, potentially reshaping clinical development and regulatory pathways, thus accelerating the delivery of innovative treatments to cancer patients. Read the full paper now: https://lnkd.in/g-QGR8vb #Cytotherapy

Curious about how our Carcino3D™ technology works? At Carcinotech Ltd, we're dedicated to accelerating the development of cancer therapeutics. Our platform enables drug developers to access physiologically and genetically relevant models much earlier in the drug development process, bypassing the need for traditional organoid and PDX models. This streamlines R&D and pre-clinical stages, ultimately bringing treatments to market faster. Watch our video to learn more about our tumour development process. #Oncology #DrugDiscovery #CancerResearch

Prof Sandi Deans (GenQA) and Dr Simon Patton (EMQN) will be presenting Lessons learned from the 2023 Worldwide EQA Scheme for Molecular Testing of BRCA and other HRR gene variants in ovarian and prostate cancer. This webinar will provide an Overview of results from the 2023 Molecular testing of BRCA and other HRR gene variants EQA schemes, clear examples of the errors and pitfalls seen in the EQA, practical solutions, which when implemented may help prevent / rectify common issues and guidance on reporting results within different clinical contexts. You can register for this webinar at https://lnkd.in/eQ9AMANg #EQA #BRCA #HRR #Quality #Genes AstraZeneca

Today was a very exciting day in the world of Biopharma, where highly effective, personalized medicines are becoming a reality! Intellia's groundbreaking CRISPR results from long-term Ph1 study of NTLA-2002 showed that this gene editing treatment for Hereditary Angiodema (HAE) has the potential to be ground-breaking- a 9% mean reduction in monthly HAE attacks and 8/10 patients attack-free months after treatment. On the same day, Moderna, in collaboration with Marck, revealed positive 3-year data for mRNA-4157- an individualized cancer therapy for high-risk melanoma patients, where the study showed a 49% reduction in risk of recurrence or death when combined w/ Keytruda (vs. Keytruda alone). Exciting wins for these companies, and for humanity as a whole!

Uncover the latest in NTRK fusion positive NSCLC management with our free, on-demand, CME-accredited program: 'Biomarker driven management of NSCLC' Including: ✅ Clinical pathway tool: Detecting and targeting NTRK fusions in NSCLC ✅ HCP and patient discussion video: the importance of shared decision making in NSCLC ✅ Practice communication aid: implementing a process for shared decision making in NSCLC to your practice Led by Fernando Lopez-Rios, and featuring expert faculty Alexander Drilon, and Caterina Marchiò and patient Alex Miles, this program aims to improve the individualised management of NSCLC through education on the detection of NTRK gene fusions, current evidence-based guidelines, and new and emerging therapies. View the content, and claim your CME-credits now at https://lnkd.in/eKBcEPFf --- This independent medical education program is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc. #NSCLC #oncology #lungcancer #lungcancerawareness #NTRK #NTRKfusion #lungbiomarkers #medicaleducation #continuingmedicaleducation #cme #independentmedicaleducation #ime #SpringerIME

This white paper reviews the current immuno-oncology landscape and offers guidance for biotech companies preparing for IO studies, including cell- and gene-based therapies. https://bit.ly/41jutxm #oncology #immunooncology #clinicalresearch #immunotherapy #biotech #genetherapy #CAGT #celltherapy #clinicaltrials

In the latest issue of Drug Target Review, our very own Daniel Kavanagh, PhD, RAC shares how T-cell receptors offer a window to the cell for a new class of cancer therapeutics. His article explores how investigational genetically engineered medicinal products are leveraging T-cell receptors to allow the immune system to monitor events inside the cell, greatly expanding potential immune targets for treating cancer and other diseases. Read the article now starting on page 20 in Drug Target Review at https://lnkd.in/dPeEXrtu #cellandgene #cancerresearch #clinicalresearch #wcg  

Mechanisms of resistance are being defined for CAR T cells. Tumor cells that emerge after GPRC5D CAR T cells could have generally decreased or lost expression of the GPRC5D target through biallelic gene loss or transcriptional down-regulation. #personaloncologia #oncologiadeprecisão -#oncologia #CART #Genômica https://nej.md/3LX7UIq

📣 Announcing Insilico's latest AI-designed cancer drug -- ISM9682 -- a highly selective oral small-molecule inhibitor of KIF18A designed by Chemistry42. ◾ Why KIF18A? KIF18A is an extremely promising pathway for addressing chromosomal instability (CIN), or persistent errors in chromosome segregation during mitosis, which is seen in virtually all types of cancer and is a common feature of solid tumors. ◾ What the data shows In preclinical studies, ISM9682 has demonstrated broad anti-tumor activity in multiple CIN cell lines and potent in vivo efficacy in multiple CDX animal models, as well as favorable oral bioavailability and a good safety margin. ◾ Potential market Insilico is evaluating the potential of ISM9682 for numerous cancer indications as well as in combination with mitotic/DNA repair inhibitors, such as Olaparib. ◾ What's next? ISM9682 will be one of 5 posters from Insilico at the upcoming American Association for Cancer Research (AACR) meeting in San Diego April 5-10 where we will present additional data. Interested in learning more? Contact: bd@insilicomedicine.com *link to full story from Alex Philippidis in Genetic Engineering & Biotechnology News in comments. #ai #genai #cancer #drugdiscovery #aacr #cin

CMIC is involved in nearly 70% of all oncology drug development in Japan, including groundbreaking genetic screening projects. As the world of science and medicine continues to evolve, CMIC is breaking new ground in genetic screening projects not only in Japan, but across the Asia-Pacific region. #GeneticScreening can make a significant impact in the oncology area by addressing unmet medical needs. These initiatives hold the potential to revolutionize the treatment and care of cancer patients. We are sharing details of two projects that hold immense promise for patients in need in the White Paper, “Genetic Screening Projects Make Japan A Rising Option For Clinical Trials.” Available now on our website: https://lnkd.in/e-URkXSg #oncology #genetics #CMIC